Objective: To explore the efficacy and safety of glucocorticoid in the treatment of early bronchopulmonary dysplasia (BPD). Methods: Clinical data of inpatients with early BPD admitted into our hospital from Jan. 2016 to Jul. 2019

gestational age 燮30 weeks and body weight 燮1

500 g

who could not be withdraw from non鄄invasive ventilator and/ or deoxygenation at 28th day after birth were retrospectively analyzed. All patients were divided into 24 cases in the dexamethasone (DXM) group

37 cases in the hydrocortisone (HC) group and 50 cases in the control group according to different treatment regimens. The control group received conventional treatment such as caffeine for apnea prevention

fluid restriction

respiratory support

nutritional support and antibiotics for infection. The HC group was given hydrocortisone sodium succinate on the basis of conventional treatment for 10 d. The DXM group was treated with dexamethasone sodium phosphate injection on the basis of the conventional treatment for 9 d. The perinatal factors

treatment process and clinical outcomes of three groups were compared. Results: Compared with the control group

the DXM group and HC group had lower birth weight and smaller gestational age (P<0.05). At 36 weeks of postmenstrual age

there was no significant difference in the proportion of BPD among three groups (P>0.05)

yet the total oxygen consumption time in the DXM group was shorter than that in the control group and the HC group (P<0.05). Conclusion: Treatment of early BPD with DXM or HC was not effective in reducing the rate of moderate to severe BPD at 36 weeks of postmenstrual age

yet application of DXM shortens the total oxygen consumption time in children with BPD.